Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with follicular lymphoma (a type of slow-growing blood cancer) grade 1, 2, or 3a, confirmed by a tissue sample test
• People whose follicular lymphoma has come back or stopped responding to treatment, and who have already tried at least two rounds of treatment — where at least one of those rounds included a combination of an anti-CD20 antibody drug and a chemotherapy drug called an alkylating agent. People whose disease has been stable (no return) for more than one year after their last treatment do not meet this requirement
• People who have at least one area of lymphoma that can be measured on a scan, following standard 2014 measurement guidelines. Areas previously treated with radiation only count if the lymphoma has clearly grown back since then
• People whose follicular lymphoma has spread to the central nervous system (brain or spinal cord) may be considered (confirm with trial site)
• People who have finished previous cancer treatments at least 2 weeks or 5 half-lives before a blood collection procedure called leukapheresis (whichever comes first), or at least 3 half-lives before leukapheresis for certain immune-based treatments (such as ipilimumab, pembrolizumab, or atezolizumab)
• People whose side effects from previous lymphoma treatments have mostly resolved and are no longer severe — except for minor issues like hair loss
• People aged 18 or older
• People who are generally well enough to carry out normal daily activities, with little or no limitation (as measured by a standard medical scoring system called ECOG, scoring 0 or 1)
• People with blood counts within acceptable ranges: enough neutrophils (a type of white blood cell), platelets, and lymphocytes (other immune cells), as measured by blood tests
• People whose kidneys, liver, lungs, and heart are functioning adequately, based on blood tests and heart scans — including normal oxygen levels at rest and no significant fluid around the heart or lungs
• Women who could become pregnant must have a negative pregnancy test before joining

Who may not be able to join:

• People whose follicular lymphoma has changed (transformed) into a more aggressive type of lymphoma
• People diagnosed with small lymphocytic lymphoma (a related but different type of blood cancer)
• People with follicular lymphoma graded as 3b (a more aggressive subtype)
• People diagnosed with lymphoplasmacytic lymphoma (another related blood cancer)
• People who have had another type of cancer in the past, unless they have been cancer-free and off cancer treatment for at least 3 years — though some exceptions apply for certain non-serious skin cancers or very early-stage cancers (such as early cervical, bladder, or breast)
• People who have had an autologous stem cell transplant (using their own stem cells) within 6 weeks before the planned treatment infusion
• People who have ever had an allogeneic stem cell transplant (using another person's stem cells)
• People who have previously received treatment that targets a protein called CD19
• People who have previously received CAR-T cell therapy or any other treatment using genetically modified T-cells
• People with a history of a severe allergic reaction to a class of antibiotics called aminoglycosides
• People with an active, uncontrolled infection (fungal, bacterial, viral, or other) that requires treatment through a drip (intravenous therapy)
• People known to have HIV, or active hepatitis B or C infection. People with a past hepatitis infection must have test results confirming the infection has cleared before being considered
• People with a known history of lymphoma involving the full wall of the stomach
• People who have a tube or drainage device currently in their body (such as a kidney drain, urinary catheter, or fluid drainage tube around the lungs or heart). Standard central line catheters used to deliver medication are allowed
• People whose lymphoma is located only in the brain or spinal cord (primary central nervous system lymphoma)
• People whose lymphoma has spread into the chambers of the heart
• People who have had a heart attack, heart surgery, unstable chest pain, moderate-to-severe heart failure, or another serious heart condition within the past 12 months
• People whose tumour is growing so quickly that an emergency is expected within 6 weeks of the blood collection procedure
• People who have had organ damage caused by an autoimmune disease (such as Crohn's disease, rheumatoid arthritis, or lupus) in the past 2 years, or who are currently taking medication to suppress the immune system. People with stable autoimmune thyroid disease on a steady hormone dose, or stable type 1 diabetes on a steady insulin dose, may still be considered
• People who have had a symptomatic blood clot in a deep vein or in the lungs within 6 months before joining, or a blood clot in an arm vein within 3 months before the start of chemotherapy given before the main treatment
• People with any other medical condition that could affect how safely or accurately the trial can be run
• People who have had a severe allergic reaction to any of the drugs used in this trial
• People who have received a live vaccine within 6 weeks before the start of preparatory chemotherapy, or who may need one during the trial
• Women who are currently breastfeeding
• People who are unwilling to use contraception from the time they sign the consent form until 6 months after finishing the preparatory chemotherapy or the trial treatment infusion

Important: Always verify eligibility with the trial site directly before applying.